» Articles » PMID: 36620072

Comparison of Busulfan and Total Body Irradiation Conditioning on Hematopoietic Clonal Dynamics Following Lentiviral Gene Transfer in Rhesus Macaques

Abstract

The clonal dynamics following hematopoietic stem progenitor cell (HSPC) transplantation with busulfan conditioning are of great interest to the development of HSPC gene therapies. Compared with total body irradiation (TBI), busulfan is less toxic and more clinically relevant. We used a genetic barcoded HSPC autologous transplantation model to investigate the impact of busulfan conditioning on hematopoietic reconstitution in rhesus macaques. Two animals received lower busulfan dose and demonstrated lower vector marking levels compared with the third animal given a higher busulfan dose, despite similar busulfan pharmacokinetic analysis. We observed uni-lineage clonal engraftment at 1 month post-transplant, replaced by multilineage clones by 2 to 3 months in all animals. The initial multilineage clones in the first two animals were replaced by a second multilineage wave at 9 months; this clonal pattern disappeared at 13 months in the first animal, though was maintained in the second animal. The third animal maintained stable multilineage clones from 3 months to the most recent time point. In addition, busulfan animals exhibit more rapid HSPC clonal mixing across bone marrow sites and less CD16 NK-biased clonal expansion compared with TBI animals. Therefore, busulfan conditioning regimens can variably impact the marrow niche, resulting in differences in clonal patterns with implications for HSPC gene therapies.

Citing Articles

Animal model considerations for chordoma research: reproducing the tumor microenvironment with humanized mice.

Campilan B, Schroeder C, Sagaityte E, Arditi J, Leary O, Ziya L Gokaslan Front Oncol. 2024; 14:1330254.

PMID: 38544830 PMC: 10965562. DOI: 10.3389/fonc.2024.1330254.


Toward effective hematopoietic stem cell gene therapies: Optimized conditioning regimen and stem cell source in harmony.

Demirci S, Tisdale J Mol Ther Methods Clin Dev. 2023; 30:411-412.

PMID: 37663647 PMC: 10470264. DOI: 10.1016/j.omtm.2023.08.005.


Efficient manufacturing and engraftment of gene-edited HSPCs following busulfan conditioning in nonhuman primates.

Murray J, Einhaus T, Venkataraman R, Radtke S, Zhen A, Carrillo M Mol Ther Methods Clin Dev. 2023; 30:276-287.

PMID: 37575091 PMC: 10415663. DOI: 10.1016/j.omtm.2023.07.006.


The unknown impact of conditioning on HSC engraftment and clonal dynamics.

Radtke S Mol Ther Methods Clin Dev. 2023; 28:385-386.

PMID: 36874241 PMC: 9982445. DOI: 10.1016/j.omtm.2023.02.005.

References
1.
Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L . Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med. 2009; 360(5):447-58. DOI: 10.1056/NEJMoa0805817. View

2.
Copelan E . Hematopoietic stem-cell transplantation. N Engl J Med. 2006; 354(17):1813-26. DOI: 10.1056/NEJMra052638. View

3.
Deola S, Scaramuzza S, Birolo R, Carballido-Perrig N, Ficara F, Mocchetti C . Mobilized blood CD34+ cells transduced and selected with a clinically applicable protocol reconstitute lymphopoiesis in SCID-Hu mice. Hum Gene Ther. 2004; 15(3):305-11. DOI: 10.1089/104303404322886156. View

4.
Frangoul H, Altshuler D, Cappellini M, Chen Y, Domm J, Eustace B . CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia. N Engl J Med. 2020; 384(3):252-260. DOI: 10.1056/NEJMoa2031054. View

5.
Ribeil J, Hacein-Bey-Abina S, Payen E, Magnani A, Semeraro M, Magrin E . Gene Therapy in a Patient with Sickle Cell Disease. N Engl J Med. 2017; 376(9):848-855. DOI: 10.1056/NEJMoa1609677. View